HIV infection in the elderly

Current Infectious Disease Reports

Volumn 11, Issue 3, 2009, Pages 246-254

  Gebo, Kelly A ^a   Justice, Amy ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; BENZODIAZEPINE DERIVATIVE; CHOLESTEROL; DELAVIRDINE; HIGH DENSITY LIPOPROTEIN; INDINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

AGED; AGING; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DRUG ANTAGONISM; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; DYSLIPIDEMIA; ELDERLY CARE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN BLOOD LEVEL; LIVER FAILURE; METABOLIC DISORDER; NEPHROTOXICITY; PREVALENCE; REVIEW; SEDATION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

EID: 65649127248     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0036-0     Document Type: Review

References (77)

1. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report, 2006, vol 18. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2008.
2. Phillips AN, Lee CA, Elford J, et al.: More rapid progression to AIDS in older HIV-infected people: The role of CD4+ T-cell counts. J Acquir Immune Defic Syndr 1991, 4:970-975.
3. Rothenberg R, Woelfel M, Stoneburner R, et al.: Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med 1987, 317:1297-1302.
4. Balslev U, Monforte AD, Stergiou G, et al.: Influence of age on rates of new AIDS-defining diseases and survival in 6546 AIDS patients. Scand J Infect Dis 1997, 29:337-343.
5. Centers for Disease Control and Prevention: AIDS among persons aged > or = 50 years - United States, 1991-1996. MMWR Morb Mortal Wkly Rep 1998, 47:21-27.
6. Manfredi R: HIV infection End advanced age: emerging epidemiological, clinical, and management issues. Ageing Res Rev 2004, 3:31-54.
7. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992, 41:1-19.
8. Mack KA, Ory MG: AIDS and older Americans at the end of the twentieth century. J Acquir Immune Defic Syndr 2003, 33(Suppl 2):S68-S75.
9. HIV Over Fifty, Exploring the New Threat: Hearings Before the Senate Committee on Aging, (statement of Senator Gordon H. Smith). Washington, DC; 2005. Accessed April 18, 2006.
10. Stall R, Catania J: AIDS risk behaviors among late middle-aged and elderly Americans. The National AIDS Behavioral Surveys. Arch Intern Med 1994, 154:57-63.
11. Ship JA, Wolff A, Selik RM: Epidemiology of acquired immune deficiency syndrome in persons aged 50 years or older. J Acquir Immune Defic Syndr 1991, 4:84-88.
12. Douek DC, McFarland RD, Keiser PH, et al.: Changes in thymic function with age and during the treatment of HIV infection. Nature 1998, 396:690-695.
13. Haynes BF, Markert ML, Sempowski GD, et al.: The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000, 18:529-560.
14. Mackall CL, Gress RE: Thymic aging and T-cell regeneration. Immunol Rev 1997, 160:91-102.
15. Zhang L, Lewin SR, Markowitz M, et al.: Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999, 190:725-732.
16. Jamieson BD, Douek DC, Killian S, et al.: Generation of functional thymocytes in the human adult. Immunity 1999, 10:569-575.
17. Manfredi R, Chiodo F: A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS 2000, 14:1475-1477.
18. Viard JP, Mocroft A, Chiesi A, et al.: Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: Evidence from the EuroSIDA study. J Infect Dis 2001, 183:1290-1294.
19. Yamashita TE, Phair JP, Munoz A, et al.: Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001, 15:735-746.
20. Grabar S, Kousignian I, Sobel A, et al.: Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004, 18:2029-2038.
21. Kaufmann GR, Furrer H, Ledergerber B, et al.: Characteristics, determinants, and clinical relevance of CD4 T cell recovery to < 500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005, 41:361-372.
22. Cuzin L, Delpierre C, Gerard S, et al.: Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged > 50 years. Clin Infect Dis 2007, 45:654-657.
23. Tumbarello M, Rabagliati R, De Gaetano Donati K, et al.: Older HIV-positive patients in the era of highly active antiretroviral therapy: Changing of a scenario. AIDS 2003, 17:128-131.
24. Tumbarello M, Rabagliati R, De Gaetano Donati K, et al.: Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active anti retroviral therapy. BMC Infect Dis 2004, 4:46.
25. Bosch RJ, Bennett K, Collier AC, et al.: Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 44:268-277.
26. Goodkin K, Shapshak P, Asthana D, et al.: Older age and plasma viral load in HIV-1 infection. AIDS 2004, 18(Suppl 1):S87-S98.
27. Knobel H, Guelar A, Valldecillo G, et al.: Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS 2001, 15:1591-1593.
28. Manfredi R, Calza L, Cocchi D, Chiodo F: Antiretroviral treatment and advanced age: Epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr 2003, 33:112-114.
29. Silverberg MJ, Leyden W, Horberg MA, et al.: Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007, 167:684-691.
30. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group: Response to combination antiretroviral therapy: variation by age. AIDS 2008, 22:1463-1473.
31. Greenbaum A, Wilson LE, Keruly JC, et al.: Effect of age and HAART regimen on clinical response in an urban cohort of HIV infected individuals. AIDS 2008, 22:2331-2339.
32. Patterson K, Napravnik S, Eron J, et al.: Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. HIV Med 2007, 8:406-410.
33. Anastos K, Barron Y, Cohen MH, et al.: The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004, 140:256-264.
34. Grabar S, Weiss L, Costagliola D: HIV infection in older patients in the HAART era. J Antimicrob Chemother 2006, 57:4-7.
35. Smit C, Geskus R, Walker S, et al.: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006, 20:741-749.
36. McGinnis KA, Fine MJ, Sharma RK, et al.: Understanding racial disparities in HIV using data from the Veterans Aging Cohort 3-Site Study and VA administrative data. Am J Public Health 2003, 93:1728-1733.
37. Sauvageone-Matre H, Bannie F, Tabah I, et al.: Pharmacokinetics of zidovudine in AIDS patients: Influence of age and hepatic disorders [abstract MBP 323]. Program and Abstracts of the 5th International Conference on AIDS (Montreal). Ottawa: International Development Research Centre; 1989.
38. Nelson MR, Katlama C, Montaner JS, et al.: The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years. AIDS 2007, 21:1273-1281.
39. Tashima KT, Horowitz JD, Rosen S: Indinavir nephropathy. N Engl J Med 1997, 336:138-140.
40. Gallant JE, Parish MA, Keruly JC, Moore RD: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005, 40:1194-1198.
41. Kiser J, Carten M, Wolfe P, et al.: Effect of lopinavir/ritonavir on the renal clearance of tenofovir in hiv-infected patients. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
42. Ogedegbe AO, Sulkowski MS: Antiretroviral-associated liver injury. Clin Liver Dis 2003, 7:475-499.
43. Fried LP, Tangen CM, Walston J, et al.: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:M146-M156.
44. Desquilbet L, Jacobson LP, Fried LP, et al.; Multicenter AIDS Cohort Study: HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 2007, 62:1279-1286.
45. Oursler KK, Sorkin JD, Smith BA, Katzel LI: Reduced aerobic capacity and physical functioning in older HIV-infected men. AIDS Res Hum Retroviruses 2006, 22:1113-1121.
46. Leng SX, Yang H, Walston JD: Decreased cell proliferation and altered cytokine production in frail older adults. Aging Clin Exp Res 2004, 16:249-252.
47. Abad LW, Schmitz HR, Parker R, Roubenoff R: Cytokine responses differ by compartment and wasting status in patients with HIV infection and healthy controls. Cytokine 2002, 18:286-293.
48. Lohse N, Hansen ABE, Pedersen G, et al.: Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007, 146:87-95.
49. Kohli R, Lo Y, Howard AA, et al.: Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005, 41:864-872.
50. Palella FJ, Baker RK, Moorman AC, et al.: Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43:27-34.
51. Justice AC, Lasky E, McGinnis KA, et al.: Medical disease and alcohol use among veterans with human immunodeficiency infection: A comparison of disease measurement strategies. Med Care 2006, 44:S52-S60.
52. McGinnis KA, Fultz SL, Skanderson M, et al.: Hepatocellular carcinoma and non-Hodgkin's lymphoma: The roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006, 24:5005-5009.
53. Fultz SL, McGinnis KA, Skanderson M, et al.: Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med 2004, 116:420-423.
54. Crothers K, Butt AA, Gibert CL, et al.; Veterans Aging Cohort: Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006, 130:1326-1333.
55. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents; 2006. Washington, DC: Department of Health and Human Services/Henry J. Kaiser Family Foundation; 2008.
56. Strategies for Management of Antiretroviral Therapy (SMART) Study Group; El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-2296.
57. Frisch M, Biggar RJ, Engels EA, et al.; AIDS-Cancer Match Registry Study Group: Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001, 285:1736-1745.
58. Biggar RJ, Kirby KA, Atkinson JH, et al.; AIDS-Cancer Match Registry Study Group: Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004, 36:861-868.
59. Long JL, Engels EA, Moore RD, Gebo KA: Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008, 22:489-496.
60. Kirk GD, Merlo C, O'Driscoll P, et al.: HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007, 45:103-110.
61. Allardice GM, Hole DJ, Brewster DH, et al.: Incidence of malignant neoplasms among HIV-infected persons in Scotland. Br J Cancer 2003, 89:505-507.
62. Bower M, Powles T, Nelson M, et al.: HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003, 17:371-375.
63. Chaturvedi AK, Pfeiffer RM, Chang L, et al.: Elevated risk of lung cancer among people with AIDS. AIDS 2007, 21:207-213.
64. Engels EA, Brock MV, Chen J, et al.: Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006, 24:1383-1388.
65. Engels EA: Human immunodeficiency virus infection, aging, and cancer. J Clin Epidemiol 2001, 54:S29-S34.
66. Herida M, Mary-Krause M, Kaphan R, et al.: Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003, 21:3447-3453.
67. Clifford GM, Polesel J, Rickenbach M, et al.; Swiss HIV Cohort Study: Cancer risk in the Swiss HIV cohort study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005, 97:425-432.
68. Gebo KA, Diener-West M, Moore RD: Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 2003, 34:165-173.
69. Smith SC Jr, Jackson R, Pearson TA, et al.: Principles for national and regional guidelines on cardiovascular disease prevention: A scientific statement from the World Heart and Stroke Forum. Circulation 2004, 109:3112-3121.
70. Holmberg SD, Moorman AC, Williamson JM, et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002, 360:1747-1748.
71. Klein D, Hurley LB, Quesenberry CP, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002, 30:471-477.
72. Holmberg SD, Moorman AC, Greenberg AE, et al.; DAD Steering Committee: Trends in rates of myocardial infarction among patients with HIV. N Engl J Med 2004, 350:730-732.
73. Coplan PM, Nikas A, Japour A, et al.: Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: An analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003, 19:449-455.
74. Bozzette SA, Ake CF, Tam HK, et al.: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702.
75. Currier JS, Taylor A, Boyd F, et al.: Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003, 33:506-512.
76. Palacios R, Santos J, Garcia A, et al.: Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med 2006, 7:10-15.
77. Goulet JL, Fultz SL, Rimland D, et al.: Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007, 45:1593-1601.